Free Trial

GE HealthCare Technologies (GEHC) Financials

GE HealthCare Technologies logo
$64.39 +1.58 (+2.52%)
As of 04/14/2025 04:00 PM Eastern
Annual Income Statements for GE HealthCare Technologies

Annual Income Statements for GE HealthCare Technologies

This table shows GE HealthCare Technologies' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
2,247 1,916 1,385 1,993
Consolidated Net Income / (Loss)
2,293 1,967 1,614 2,050
Net Income / (Loss) Continuing Operations
2,275 1,949 1,618 2,050
Total Pre-Tax Income
2,875 2,512 2,361 2,581
Total Operating Income
2,795 2,522 2,435 2,625
Total Gross Profit
7,174 7,179 7,922 8,205
Total Revenue
17,585 18,341 19,552 19,672
Operating Revenue
17,585 18,341 19,552 19,672
Total Cost of Revenue
10,411 11,162 11,630 11,467
Operating Cost of Revenue
10,411 11,162 11,630 11,467
Total Operating Expenses
4,379 4,657 5,487 5,580
Selling, General & Admin Expense
3,563 3,631 4,282 4,269
Research & Development Expense
816 1,026 1,205 1,311
Total Other Income / (Expense), net
80 -10 -74 -43
Interest Expense
40 77 542 504
Other Income / (Expense), net
120 67 468 461
Income Tax Expense
600 563 743 531
Net Income / (Loss) Discontinued Operations
18 18 -4.00 0.00
Preferred Stock Dividends Declared
0.00 0.00 183 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest
46 51 46 57
Basic Earnings per Share
$4.95 $4.22 $3.05 $4.37
Weighted Average Basic Shares Outstanding
454M 454M 455M 456M
Diluted Earnings per Share
$4.95 $4.22 $3.03 $4.34
Weighted Average Diluted Shares Outstanding
454M 454M 458M 459M
Weighted Average Basic & Diluted Shares Outstanding
- - 455.36M 457.30M
Cash Dividends to Common per Share
- - $0.12 $0.13

Quarterly Income Statements for GE HealthCare Technologies

This table shows GE HealthCare Technologies' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
487 - 189 418 375 403 374 428 470 721
Consolidated Net Income / (Loss)
493 - 383 433 382 416 388 435 490 737
Net Income / (Loss) Continuing Operations
493 - 383 433 386 416 388 435 490 737
Total Pre-Tax Income
622 - 546 570 636 609 512 578 658 833
Total Operating Income
605 - 559 570 617 689 540 608 676 801
Total Gross Profit
1,773 - 1,891 1,940 1,935 2,156 1,902 2,002 2,026 2,275
Total Revenue
4,576 - 4,707 4,817 4,822 5,206 4,650 4,839 4,863 5,320
Operating Revenue
4,576 - 4,707 4,817 4,822 5,206 4,650 4,839 4,863 5,320
Total Cost of Revenue
2,803 - 2,816 2,877 2,887 3,050 2,749 2,837 2,838 3,043
Operating Cost of Revenue
2,803 - 2,816 2,877 2,887 3,050 2,749 2,837 2,838 3,043
Total Operating Expenses
1,168 - 1,332 1,370 1,318 1,467 1,362 1,394 1,350 1,474
Selling, General & Admin Expense
908 - 1,062 1,072 996 1,152 1,038 1,067 1,034 1,130
Research & Development Expense
260 - 270 298 322 315 324 327 316 344
Total Other Income / (Expense), net
17 - -13 0.00 19 -80 -28 -29 -19 33
Interest Expense
2.00 - 136 137 138 131 122 131 130 121
Other Income / (Expense), net
19 - 123 137 157 51 94 102 111 154
Income Tax Expense
129 - 163 137 250 193 124 143 168 96
Net Income / (Loss) Attributable to Noncontrolling Interest
6.00 - 11 15 7.00 13 14 7.00 19 17
Basic Earnings per Share
$1.07 - $0.42 $0.92 $0.82 $0.89 $0.82 $0.94 $1.03 $1.58
Weighted Average Basic Shares Outstanding
454M 454M 454M 455M 455M 455M 456M 457M 457M 456M
Diluted Earnings per Share
$1.07 - $0.41 $0.91 $0.82 $0.89 $0.81 $0.93 $1.02 $1.58
Weighted Average Diluted Shares Outstanding
454M 454M 457M 458M 458M 458M 459M 459M 459M 459M
Weighted Average Basic & Diluted Shares Outstanding
- 0.00 - - 455.24M 455.36M 456.47M 456.66M 456.87M 457.30M

Annual Cash Flow Statements for GE HealthCare Technologies

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024
Net Change in Cash & Equivalents
-451 890 1,055 387
Net Cash From Operating Activities
1,607 2,113 2,101 1,951
Net Cash From Continuing Operating Activities
1,607 2,134 2,101 1,955
Net Income / (Loss) Continuing Operations
2,275 1,949 1,618 2,050
Consolidated Net Income / (Loss)
2,293 1,967 1,614 2,050
Net Income / (Loss) Discontinued Operations
18 18 -4.00 0.00
Depreciation Expense
225 228 248 268
Amortization Expense
400 405 362 312
Non-Cash Adjustments To Reconcile Net Income
45 -263 -390 -585
Changes in Operating Assets and Liabilities, net
-1,338 -185 263 -91
Net Cash From Discontinued Operating Activities
0.00 -21 0.00 -4.00
Net Cash From Investing Activities
-1,761 -398 -558 -914
Net Cash From Continuing Investing Activities
-1,761 -398 -558 -914
Purchase of Property, Plant & Equipment
-248 -310 -387 -401
Acquisitions
-1,481 0.00 -147 -313
Purchase of Investments
- -59 -48 -40
Sale of Property, Plant & Equipment
15 4.00 1.00 0.00
Other Investing Activities, net
-47 -33 23 -160
Net Cash From Financing Activities
-263 -822 -478 -573
Net Cash From Continuing Financing Activities
-263 -822 -478 -572
Repayment of Debt
-23 -95 -904 -1,452
Repurchase of Common Equity
0.00 0.00 -211 0.00
Payment of Dividends
0.00 0.00 -41 -55
Issuance of Debt
-2.00 8,207 1,994 995
Issuance of Common Equity
- 0.00 34 33
Other Financing Activities, net
-238 -8,934 -1,350 -93
Effect of Exchange Rate Changes
-34 -3.00 -10 -77
Cash Interest Paid
21 0.00 570 550

Quarterly Cash Flow Statements for GE HealthCare Technologies

This table details how cash moves in and out of GE HealthCare Technologies' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
- 947 883 -389 475 86 59 -547 1,554 -679
Net Cash From Operating Activities
- 1,042 468 -67 650 1,050 419 -119 738 913
Net Cash From Continuing Operating Activities
- 1,063 468 -67 650 1,050 419 -121 744 913
Net Income / (Loss) Continuing Operations
- 567 383 433 386 416 388 435 489 738
Consolidated Net Income / (Loss)
- 573 383 433 382 416 388 435 489 738
Depreciation Expense
- 59 61 63 64 60 68 69 66 65
Amortization Expense
- 98 96 93 89 84 80 80 77 75
Non-Cash Adjustments To Reconcile Net Income
- -15 -101 -216 -64 -9.00 -155 -202 -91 -137
Changes in Operating Assets and Liabilities, net
- 354 29 -440 175 499 38 -503 203 171
Net Cash From Investing Activities
- -95 -266 -84 -120 -88 -188 -349 -137 -240
Net Cash From Continuing Investing Activities
- -95 -266 -84 -120 -88 -187 -350 -137 -240
Purchase of Property, Plant & Equipment
- -77 -143 -70 -80 -94 -145 -64 -90 -102
Acquisitions
- - -127 -20 - - 0.00 -259 - -54
Purchase of Investments
- - - - - -27 - - - -7.00
Other Investing Activities, net
- 40 4.00 5.00 -19 33 -42 -27 -14 -77
Net Cash From Financing Activities
- -37 673 -227 -24 -900 -153 -57 914 -1,277
Net Cash From Continuing Financing Activities
- -37 673 -227 -24 -900 -153 -57 914 -1,276
Repayment of Debt
- -2.00 -1.00 1.00 -33 -871 -141 -42 -7.00 -1,262
Payment of Dividends
- - 0.00 -14 -14 -13 -14 -14 -13 -14
Issuance of Debt
- 8,196 1,991 -3.00 23 -17 2.00 -1.00 993 1.00
Issuance of Common Equity
- - - - - 3.00 - - - 2.00
Other Financing Activities, net
- -8,231 -1,317 - -31 -2.00 0.00 - -90 -3.00
Effect of Exchange Rate Changes
- 37 8.00 -11 -31 24 -19 -22 39 -75
Cash Interest Paid
- - 42 208 68 252 55 219 65 211

Annual Balance Sheets for GE HealthCare Technologies

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
27,539 32,454 33,089
Total Current Assets
8,318 9,410 9,901
Cash & Equivalents
1,445 2,504 2,889
Accounts Receivable
3,312 3,557 3,569
Inventories, net
2,155 1,960 1,939
Other Current Assets
1,406 1,389 1,503
Plant, Property, & Equipment, net
2,314 2,500 2,550
Total Noncurrent Assets
16,907 20,544 20,638
Goodwill
12,813 12,936 13,136
Intangible Assets
1,520 1,253 1,078
Noncurrent Deferred & Refundable Income Taxes
1,550 4,474 4,474
Other Noncurrent Operating Assets
1,024 1,881 1,950
Total Liabilities & Shareholders' Equity
27,539 32,454 33,089
Total Liabilities
17,947 25,144 24,437
Total Current Liabilities
7,191 8,981 9,553
Short-Term Debt
15 1,006 1,502
Accounts Payable
2,944 2,947 3,022
Current Employee Benefit Liabilities
- 1,518 1,521
Other Current Liabilities
4,232 3,510 3,508
Total Noncurrent Liabilities
10,756 16,163 14,884
Long-Term Debt
8,234 8,436 7,449
Noncurrent Deferred & Payable Income Tax Liabilities
370 68 56
Noncurrent Employee Benefit Liabilities
549 5,782 5,583
Other Noncurrent Operating Liabilities
1,603 1,877 1,796
Commitments & Contingencies
0.00 0.00 0.00
Redeemable Noncontrolling Interest
230 165 188
Total Equity & Noncontrolling Interests
9,362 7,145 8,464
Total Preferred & Common Equity
9,357 7,133 8,446
Total Common Equity
9,357 7,133 8,446
Common Stock
0.00 6,498 6,588
Retained Earnings
0.00 1,326 3,262
Treasury Stock
- 0.00 -25
Accumulated Other Comprehensive Income / (Loss)
-1,878 -691 -1,379
Noncontrolling Interest
5.00 12 18

Quarterly Balance Sheets for GE HealthCare Technologies

This table presents GE HealthCare Technologies' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Total Assets
27,539 32,382 32,454 32,208 31,852 33,855 33,089
Total Current Assets
8,318 9,468 9,410 9,373 8,806 10,638 9,901
Cash & Equivalents
1,445 2,418 2,504 2,563 2,015 3,568 2,889
Accounts Receivable
3,312 3,400 3,557 3,344 3,354 3,424 3,569
Inventories, net
2,155 2,128 1,960 1,989 2,023 2,124 1,939
Other Current Assets
1,406 1,522 1,389 1,478 1,414 1,522 1,503
Plant, Property, & Equipment, net
2,314 2,355 2,500 2,445 2,458 2,539 2,550
Total Noncurrent Assets
16,907 20,559 20,544 20,392 20,589 20,677 20,638
Goodwill
12,813 12,914 12,936 12,927 13,116 13,138 13,136
Intangible Assets
1,520 1,332 1,253 1,174 1,195 1,132 1,078
Noncurrent Deferred & Refundable Income Taxes
1,550 4,277 4,474 4,413 4,365 4,309 4,474
Other Noncurrent Operating Assets
1,024 2,036 1,881 1,878 1,913 2,098 1,950
Total Liabilities & Shareholders' Equity
27,539 32,382 32,454 32,208 31,852 33,855 33,089
Total Liabilities
17,947 25,079 25,144 24,609 23,858 25,343 24,437
Total Current Liabilities
7,191 7,565 8,981 8,859 8,318 8,670 9,553
Short-Term Debt
15 7.00 1,006 1,008 1,007 1,007 1,502
Accounts Payable
2,944 2,774 2,947 2,931 2,824 2,911 3,022
Current Employee Benefit Liabilities
- - 1,518 - 1,235 1,422 1,521
Other Current Liabilities
4,232 4,784 3,510 4,920 3,251 3,331 3,508
Total Noncurrent Liabilities
10,756 17,514 16,163 15,751 15,539 16,673 14,884
Long-Term Debt
8,234 10,253 8,436 8,247 8,233 9,306 7,449
Noncurrent Deferred & Payable Income Tax Liabilities
370 62 68 68 55 59 56
Noncurrent Employee Benefit Liabilities
549 5,373 5,782 5,625 5,455 5,388 5,583
Other Noncurrent Operating Liabilities
1,603 1,826 1,877 1,811 1,796 1,920 1,796
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
230 161 165 177 177 177 188
Total Equity & Noncontrolling Interests
9,362 7,142 7,145 7,423 7,817 8,335 8,464
Total Preferred & Common Equity
9,357 7,131 7,133 7,408 7,801 8,317 8,446
Total Common Equity
9,357 7,131 7,133 7,409 7,801 8,318 8,446
Common Stock
0.00 6,474 6,498 6,509 6,545 6,556 6,588
Retained Earnings
0.00 937 1,326 1,687 2,101 2,558 3,262
Treasury Stock
- - 0.00 - - -25 -25
Accumulated Other Comprehensive Income / (Loss)
-1,878 -280 -691 -787 -845 -771 -1,379
Noncontrolling Interest
5.00 11 12 14 16 18 18

Annual Metrics and Ratios for GE HealthCare Technologies

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric 2021 2022 2023 2024
Growth Metrics
- - - -
Revenue Growth
0.00% 4.30% 6.60% 0.61%
EBITDA Growth
0.00% -8.98% 9.03% 4.36%
EBIT Growth
0.00% -11.18% 12.13% 6.30%
NOPAT Growth
0.00% -11.53% -14.72% 24.94%
Net Income Growth
0.00% -14.22% -17.95% 27.01%
EPS Growth
0.00% -14.75% -28.20% 43.23%
Operating Cash Flow Growth
0.00% 31.49% -0.57% -7.14%
Free Cash Flow Firm Growth
0.00% 0.00% 126.43% -57.56%
Invested Capital Growth
0.00% 0.00% -13.10% 3.26%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.58%
EBITDA Q/Q Growth
0.00% 0.00% 463.88% 6.11%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 7.49%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 13.10%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 18.57%
EPS Q/Q Growth
0.00% 0.00% 0.00% 18.90%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.38% -6.56%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -6.55%
Invested Capital Q/Q Growth
0.00% 0.00% -5.92% -3.55%
Profitability Metrics
- - - -
Gross Margin
40.80% 39.14% 40.52% 41.71%
EBITDA Margin
20.13% 17.57% 17.97% 18.64%
Operating Margin
15.89% 13.75% 12.45% 13.34%
EBIT Margin
16.58% 14.12% 14.85% 15.69%
Profit (Net Income) Margin
13.04% 10.72% 8.25% 10.42%
Tax Burden Percent
79.76% 78.30% 68.36% 79.43%
Interest Burden Percent
98.63% 97.03% 81.33% 83.64%
Effective Tax Rate
20.87% 22.41% 31.47% 20.57%
Return on Invested Capital (ROIC)
0.00% 23.87% 10.89% 14.40%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 24.17% 10.09% 13.86%
Return on Net Nonoperating Assets (RNNOA)
0.00% 17.14% 8.21% 11.29%
Return on Equity (ROE)
0.00% 41.01% 19.10% 25.69%
Cash Return on Invested Capital (CROIC)
0.00% -176.13% 24.91% 11.19%
Operating Return on Assets (OROA)
0.00% 9.40% 9.68% 9.42%
Return on Assets (ROA)
0.00% 7.14% 5.38% 6.26%
Return on Common Equity (ROCE)
0.00% 40.01% 18.63% 25.07%
Return on Equity Simple (ROE_SIMPLE)
0.00% 21.02% 22.63% 24.27%
Net Operating Profit after Tax (NOPAT)
2,212 1,957 1,669 2,085
NOPAT Margin
12.58% 10.67% 8.53% 10.60%
Net Nonoperating Expense Percent (NNEP)
0.00% -0.30% 0.80% 0.54%
Return On Investment Capital (ROIC_SIMPLE)
- 11.11% 10.06% 11.97%
Cost of Revenue to Revenue
59.20% 60.86% 59.48% 58.29%
SG&A Expenses to Revenue
20.26% 19.80% 21.90% 21.70%
R&D to Revenue
4.64% 5.59% 6.16% 6.66%
Operating Expenses to Revenue
24.90% 25.39% 28.06% 28.37%
Earnings before Interest and Taxes (EBIT)
2,915 2,589 2,903 3,086
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3,540 3,222 3,513 3,666
Valuation Ratios
- - - -
Price to Book Value (P/BV)
0.00 0.00 4.91 4.20
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 1.79 1.80
Price to Earnings (P/E)
0.00 0.00 25.29 17.80
Dividend Yield
0.00% 0.00% 0.12% 0.15%
Earnings Yield
0.00% 0.00% 3.95% 5.62%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 2.96 2.84
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 2.16 2.12
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 12.00 11.39
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 14.52 13.53
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 25.26 20.02
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 20.06 21.39
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 11.04 25.77
Leverage & Solvency
- - - -
Debt to Equity
0.00 0.86 1.29 1.03
Long-Term Debt to Equity
0.00 0.86 1.15 0.86
Financial Leverage
0.00 0.71 0.81 0.81
Leverage Ratio
0.00 2.87 3.55 4.11
Compound Leverage Factor
0.00 2.79 2.89 3.43
Debt to Total Capital
0.00% 46.24% 56.36% 50.85%
Short-Term Debt to Total Capital
0.00% 0.08% 6.01% 8.53%
Long-Term Debt to Total Capital
0.00% 46.15% 50.36% 42.32%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 1.32% 1.06% 1.17%
Common Equity to Total Capital
0.00% 52.45% 42.58% 47.98%
Debt to EBITDA
0.00 2.56 2.69 2.44
Net Debt to EBITDA
0.00 2.11 1.98 1.65
Long-Term Debt to EBITDA
0.00 2.56 2.40 2.03
Debt to NOPAT
0.00 4.22 5.66 4.29
Net Debt to NOPAT
0.00 3.48 4.16 2.91
Long-Term Debt to NOPAT
0.00 4.21 5.06 3.57
Altman Z-Score
0.00 0.00 1.81 1.92
Noncontrolling Interest Sharing Ratio
0.00% 2.45% 2.44% 2.40%
Liquidity Ratios
- - - -
Current Ratio
0.00 1.16 1.05 1.04
Quick Ratio
0.00 0.66 0.67 0.68
Cash Flow Metrics
- - - -
Free Cash Flow to Firm (FCFF)
0.00 -14,439 3,817 1,620
Operating Cash Flow to CapEx
689.70% 690.52% 544.30% 486.53%
Free Cash Flow to Firm to Interest Expense
0.00 -187.52 7.04 3.21
Operating Cash Flow to Interest Expense
40.18 27.44 3.88 3.87
Operating Cash Flow Less CapEx to Interest Expense
34.35 23.47 3.16 3.08
Efficiency Ratios
- - - -
Asset Turnover
0.00 0.67 0.65 0.60
Accounts Receivable Turnover
0.00 5.54 5.69 5.52
Inventory Turnover
0.00 5.18 5.65 5.88
Fixed Asset Turnover
0.00 7.93 8.12 7.79
Accounts Payable Turnover
0.00 3.79 3.95 3.84
Days Sales Outstanding (DSO)
0.00 65.91 64.12 66.11
Days Inventory Outstanding (DIO)
0.00 70.47 64.57 62.05
Days Payable Outstanding (DPO)
0.00 96.27 92.44 95.00
Cash Conversion Cycle (CCC)
0.00 40.11 36.25 33.16
Capital & Investment Metrics
- - - -
Invested Capital
0.00 16,396 14,248 14,713
Invested Capital Turnover
0.00 2.24 1.28 1.36
Increase / (Decrease) in Invested Capital
0.00 16,396 -2,148 465
Enterprise Value (EV)
0.00 0.00 42,147 41,741
Market Capitalization
0.00 0.00 35,032 35,473
Book Value per Share
$0.00 $20.61 $15.67 $18.49
Tangible Book Value per Share
$0.00 ($10.96) ($15.50) ($12.63)
Total Capital
0.00 17,841 16,752 17,603
Total Debt
0.00 8,249 9,442 8,951
Total Long-Term Debt
0.00 8,234 8,436 7,449
Net Debt
0.00 6,804 6,938 6,062
Capital Expenditures (CapEx)
233 306 386 401
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -303 -1,069 -1,039
Debt-free Net Working Capital (DFNWC)
0.00 1,142 1,435 1,850
Net Working Capital (NWC)
0.00 1,127 429 348
Net Nonoperating Expense (NNE)
-81 -10 55 35
Net Nonoperating Obligations (NNO)
0.00 6,804 6,938 6,061
Total Depreciation and Amortization (D&A)
625 633 610 580
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -1.65% -5.47% -5.28%
Debt-free Net Working Capital to Revenue
0.00% 6.23% 7.34% 9.40%
Net Working Capital to Revenue
0.00% 6.14% 2.19% 1.77%
Earnings Adjustments
- - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $3.05 $4.37
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 455M 456M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $3.03 $4.34
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 458M 459M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 455.36M 457.30M
Normalized Net Operating Profit after Tax (NOPAT)
2,212 1,957 1,669 2,085
Normalized NOPAT Margin
12.58% 10.67% 8.53% 10.60%
Pre Tax Income Margin
16.35% 13.70% 12.08% 13.12%
Debt Service Ratios
- - - -
EBIT to Interest Expense
72.88 33.62 5.36 6.12
NOPAT to Interest Expense
55.29 25.41 3.08 4.14
EBIT Less CapEx to Interest Expense
67.05 29.65 4.64 5.33
NOPAT Less CapEx to Interest Expense
49.47 21.44 2.37 3.34
Payout Ratios
- - - -
Dividend Payout Ratio
0.00% 0.00% 2.54% 2.68%
Augmented Payout Ratio
0.00% 0.00% 15.61% 2.68%

Quarterly Metrics and Ratios for GE HealthCare Technologies

This table displays calculated financial ratios and metrics derived from GE HealthCare Technologies' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 5.38% 0.00% -1.21% 0.46% 0.85% 2.19%
EBITDA Growth
0.00% 0.00% 0.00% 0.00% 48.56% 463.06% -6.79% -0.46% 0.32% 23.87%
EBIT Growth
0.00% 0.00% 0.00% 0.00% 24.04% 0.00% -7.04% 0.42% 1.68% 29.05%
NOPAT Growth
0.00% 0.00% 0.00% 0.00% -21.91% 0.00% 4.36% 5.68% 34.43% 50.58%
Net Income Growth
0.00% 0.00% 0.00% 0.00% -22.52% 0.00% 1.31% 0.46% 28.27% 77.16%
EPS Growth
0.00% 0.00% 0.00% 0.00% -23.36% 0.00% 97.56% 2.20% 24.39% 77.53%
Operating Cash Flow Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.77% -10.47% -77.61% 13.54% -13.05%
Free Cash Flow Firm Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 102.66% -90.69%
Invested Capital Growth
0.00% 0.00% 0.00% 0.00% 0.00% -13.10% 0.00% 0.00% 0.73% 3.26%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 2.34% 0.10% 7.96% 0.00% 4.06% 0.50% 9.40%
EBITDA Q/Q Growth
0.00% -74.84% 434.39% 2.86% 7.42% -4.64% 443.06% 9.85% 8.27% 17.74%
EBIT Q/Q Growth
0.00% -100.00% 0.00% 3.67% 9.48% -4.39% 0.00% 11.99% 10.85% 21.35%
NOPAT Q/Q Growth
0.00% -100.00% 0.00% 10.43% -13.52% 25.68% 0.00% 11.82% 10.02% 40.78%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 13.05% -11.78% 8.90% 0.00% 12.11% 12.64% 50.41%
EPS Q/Q Growth
0.00% 0.00% 0.00% 121.95% -9.89% 8.54% 0.00% 14.81% 9.68% 54.90%
Operating Cash Flow Q/Q Growth
0.00% 0.00% -55.09% -114.32% 1,070.15% 61.54% -60.10% -128.40% 720.17% 23.71%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 117.73% -746.36% -6.34% 102.66% -38.06%
Invested Capital Q/Q Growth
0.00% 0.00% -100.00% 0.00% 0.00% -5.92% 0.32% 6.50% 0.22% -3.55%
Profitability Metrics
- - - - - - - - - -
Gross Margin
38.75% 0.00% 40.17% 40.27% 40.13% 41.41% 40.90% 41.37% 41.66% 42.76%
EBITDA Margin
13.64% 0.00% 17.82% 17.92% 19.22% 16.98% 16.82% 17.75% 19.12% 20.58%
Operating Margin
13.22% 0.00% 11.88% 11.83% 12.80% 13.23% 11.61% 12.56% 13.90% 15.06%
EBIT Margin
13.64% 0.00% 14.49% 14.68% 16.05% 14.21% 13.63% 14.67% 16.18% 17.95%
Profit (Net Income) Margin
10.77% 0.00% 8.14% 8.99% 7.92% 7.99% 8.34% 8.99% 10.08% 13.85%
Tax Burden Percent
79.26% 0.00% 70.15% 75.96% 60.06% 68.31% 75.78% 75.26% 74.47% 88.48%
Interest Burden Percent
99.68% 0.00% 80.06% 80.62% 82.17% 82.30% 80.76% 81.41% 83.61% 87.23%
Effective Tax Rate
20.74% 0.00% 29.85% 24.04% 39.31% 31.69% 24.22% 24.74% 25.53% 11.52%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 11.54% 24.01% 24.25% 13.32% 18.10%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 10.74% 23.37% 23.62% 13.14% 18.53%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 8.73% 20.58% 21.36% 12.11% 15.09%
Return on Equity (ROE)
0.00% 0.00% 0.00% 0.00% 0.00% 20.27% 44.59% 45.61% 25.43% 33.19%
Cash Return on Invested Capital (CROIC)
0.00% -88.07% 0.00% 0.00% 0.00% 24.91% -176.42% -177.56% 11.40% 11.19%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 9.27% 16.51% 17.98% 9.56% 10.78%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 5.21% 10.10% 11.02% 5.95% 8.32%
Return on Common Equity (ROCE)
0.00% 0.00% 0.00% 0.00% 0.00% 19.78% 43.47% 44.51% 24.85% 32.39%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 21.85% 20.78% 20.79% 0.00%
Net Operating Profit after Tax (NOPAT)
480 0.00 392 433 374 471 409 458 503 709
NOPAT Margin
10.48% 0.00% 8.33% 8.99% 7.77% 9.04% 8.80% 9.46% 10.35% 13.32%
Net Nonoperating Expense Percent (NNEP)
0.00% 0.00% 0.00% 0.00% -0.19% 0.80% 0.63% 0.62% 0.18% -0.44%
Return On Investment Capital (ROIC_SIMPLE)
- 0.00% - - - 2.84% - - - 4.07%
Cost of Revenue to Revenue
61.25% 0.00% 59.83% 59.73% 59.87% 58.59% 59.12% 58.63% 58.36% 57.20%
SG&A Expenses to Revenue
19.84% 0.00% 22.56% 22.25% 20.66% 22.13% 22.32% 22.05% 21.26% 21.24%
R&D to Revenue
5.68% 0.00% 5.74% 6.19% 6.68% 6.05% 6.97% 6.76% 6.50% 6.47%
Operating Expenses to Revenue
25.52% 0.00% 28.30% 28.44% 27.33% 28.18% 29.29% 28.81% 27.76% 27.71%
Earnings before Interest and Taxes (EBIT)
624 0.00 682 707 774 740 634 710 787 955
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
624 157 839 863 927 884 782 859 930 1,095
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 4.32 4.91 5.57 4.53 5.12 4.20
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 1.79 2.12 1.81 2.18 1.80
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 25.29 26.28 22.38 25.43 17.80
Dividend Yield
0.00% 0.00% 0.00% 0.04% 0.09% 0.12% 0.13% 0.19% 0.13% 0.15%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 3.95% 3.81% 4.47% 3.93% 5.62%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 2.56 2.96 3.37 2.81 3.25 2.84
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 2.16 2.47 2.19 2.53 2.12
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 62.34 12.00 13.93 12.39 14.33 11.39
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 14.52 16.86 14.97 17.25 13.53
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 25.26 28.57 25.05 26.87 20.02
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 18.56 20.06 23.46 21.39 23.72 21.39
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 11.04 0.00 0.00 28.57 25.77
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.86 0.00 0.00 1.40 1.29 1.22 1.16 1.21 1.03
Long-Term Debt to Equity
0.00 0.86 0.00 0.00 1.40 1.15 1.09 1.03 1.09 0.86
Financial Leverage
0.00 0.71 0.00 0.00 1.07 0.81 0.88 0.90 0.92 0.81
Leverage Ratio
0.00 2.87 0.00 0.00 4.43 3.55 4.24 3.98 4.19 4.11
Compound Leverage Factor
0.00 0.00 0.00 0.00 3.64 2.92 3.42 3.24 3.50 3.58
Debt to Total Capital
0.00% 46.24% 0.00% 0.00% 58.42% 56.36% 54.91% 53.61% 54.78% 50.85%
Short-Term Debt to Total Capital
0.00% 0.08% 0.00% 0.00% 0.04% 6.01% 5.98% 5.84% 5.35% 8.53%
Long-Term Debt to Total Capital
0.00% 46.15% 0.00% 0.00% 58.38% 50.36% 48.93% 47.77% 49.43% 42.32%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 1.32% 0.00% 0.00% 0.98% 1.06% 1.13% 1.12% 1.04% 1.17%
Common Equity to Total Capital
0.00% 52.45% 0.00% 0.00% 40.60% 42.58% 43.96% 45.27% 44.19% 47.98%
Debt to EBITDA
0.00 2.56 0.00 0.00 16.47 2.69 2.68 2.68 2.98 2.44
Net Debt to EBITDA
0.00 2.11 0.00 0.00 12.59 1.98 1.94 2.09 1.95 1.65
Long-Term Debt to EBITDA
0.00 2.56 0.00 0.00 16.46 2.40 2.39 2.39 2.69 2.03
Debt to NOPAT
0.00 4.22 0.00 0.00 0.00 5.66 5.49 5.41 5.59 4.29
Net Debt to NOPAT
0.00 3.48 0.00 0.00 0.00 4.16 3.97 4.23 3.66 2.91
Long-Term Debt to NOPAT
0.00 4.21 0.00 0.00 0.00 5.06 4.89 4.82 5.05 3.57
Altman Z-Score
0.00 0.00 0.00 0.00 0.93 1.59 1.77 1.69 1.84 1.71
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 2.36% 2.44% 2.51% 2.41% 2.31% 2.40%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
0.00 1.16 0.00 0.00 1.25 1.05 1.06 1.06 1.23 1.04
Quick Ratio
0.00 0.66 0.00 0.00 0.77 0.67 0.67 0.65 0.81 0.68
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 0.00 0.00 0.00 -14,771 2,619 -13,884 -14,764 393 244
Operating Cash Flow to CapEx
0.00% 1,371.05% 327.27% -95.71% 812.50% 1,117.02% 288.97% -185.94% 820.00% 895.10%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 -107.03 19.99 -113.80 -112.71 3.03 2.01
Operating Cash Flow to Interest Expense
0.00 0.00 3.44 -0.49 4.71 8.02 3.43 -0.91 5.68 7.55
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 2.39 -1.00 4.13 7.30 2.25 -1.40 4.98 6.70
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.00 0.67 0.00 0.00 0.00 0.65 1.21 1.23 0.59 0.60
Accounts Receivable Turnover
0.00 5.54 0.00 0.00 0.00 5.69 0.00 0.00 5.73 5.52
Inventory Turnover
0.00 5.18 0.00 0.00 0.00 5.65 0.00 0.00 5.40 5.88
Fixed Asset Turnover
0.00 7.93 0.00 0.00 0.00 8.12 0.00 0.00 7.99 7.79
Accounts Payable Turnover
0.00 3.79 0.00 0.00 0.00 3.95 0.00 0.00 4.04 3.84
Days Sales Outstanding (DSO)
0.00 65.91 0.00 0.00 0.00 64.12 0.00 0.00 63.68 66.11
Days Inventory Outstanding (DIO)
0.00 70.47 0.00 0.00 0.00 64.57 0.00 0.00 67.63 62.05
Days Payable Outstanding (DPO)
0.00 96.27 0.00 0.00 0.00 92.44 0.00 0.00 90.42 95.00
Cash Conversion Cycle (CCC)
0.00 40.11 0.00 0.00 0.00 36.25 0.00 0.00 40.88 33.16
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
0.00 16,396 0.00 0.00 15,145 14,248 14,293 15,222 15,255 14,713
Invested Capital Turnover
0.00 1.12 0.00 0.00 0.00 1.28 2.73 2.56 1.29 1.36
Increase / (Decrease) in Invested Capital
0.00 0.00 0.00 0.00 15,145 -2,148 14,293 15,222 110 465
Enterprise Value (EV)
0.00 0.00 37,163 36,805 38,840 42,147 48,135 42,775 49,527 41,741
Market Capitalization
0.00 0.00 37,163 36,805 30,826 35,032 41,252 35,357 42,587 35,473
Book Value per Share
$0.00 $20.61 $0.00 $0.00 $15.67 $15.67 $16.25 $17.09 $18.21 $18.49
Tangible Book Value per Share
$0.00 ($10.96) $0.00 $0.00 ($15.64) ($15.50) ($14.68) ($14.26) ($13.03) ($12.63)
Total Capital
0.00 17,841 0.00 0.00 17,563 16,752 16,855 17,234 18,825 17,603
Total Debt
0.00 8,249 0.00 0.00 10,260 9,442 9,255 9,240 10,313 8,951
Total Long-Term Debt
0.00 8,234 0.00 0.00 10,253 8,436 8,247 8,233 9,306 7,449
Net Debt
0.00 6,804 0.00 0.00 7,842 6,938 6,692 7,225 6,745 6,062
Capital Expenditures (CapEx)
0.00 76 143 70 80 94 145 64 90 102
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -303 0.00 0.00 -508 -1,069 -1,041 -520 -593 -1,039
Debt-free Net Working Capital (DFNWC)
0.00 1,142 0.00 0.00 1,910 1,435 1,522 1,495 2,975 1,850
Net Working Capital (NWC)
0.00 1,127 0.00 0.00 1,903 429 514 488 1,968 348
Net Nonoperating Expense (NNE)
-13 0.00 9.12 0.00 -7.53 55 21 23 13 -28
Net Nonoperating Obligations (NNO)
0.00 6,804 0.00 0.00 7,842 6,938 6,693 7,228 6,743 6,061
Total Depreciation and Amortization (D&A)
0.00 157 157 156 153 144 148 149 143 140
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -1.65% 0.00% 0.00% 0.00% -5.47% -5.34% -2.66% -3.03% -5.28%
Debt-free Net Working Capital to Revenue
0.00% 6.23% 0.00% 0.00% 0.00% 7.34% 7.81% 7.66% 15.21% 9.40%
Net Working Capital to Revenue
0.00% 6.14% 0.00% 0.00% 0.00% 2.19% 2.64% 2.50% 10.06% 1.77%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.82 $0.89 $0.82 $0.94 $1.03 $1.58
Adjusted Weighted Average Basic Shares Outstanding
0.00 454M 0.00 0.00 455M 455M 456M 457M 457M 456M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.82 $0.89 $0.81 $0.93 $1.02 $1.58
Adjusted Weighted Average Diluted Shares Outstanding
0.00 454M 0.00 0.00 458M 458M 459M 459M 459M 459M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 0.00 455.24M 455.36M 456.47M 456.66M 456.87M 457.30M
Normalized Net Operating Profit after Tax (NOPAT)
480 0.00 392 433 374 471 409 458 503 709
Normalized NOPAT Margin
10.48% 0.00% 8.33% 8.99% 7.77% 9.04% 8.80% 9.46% 10.35% 13.32%
Pre Tax Income Margin
13.59% 0.00% 11.60% 11.83% 13.19% 11.70% 11.01% 11.94% 13.53% 15.66%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
312.00 0.00 5.01 5.16 5.61 5.65 5.20 5.42 6.05 7.89
NOPAT to Interest Expense
239.76 0.00 2.88 3.16 2.71 3.59 3.35 3.49 3.87 5.86
EBIT Less CapEx to Interest Expense
312.00 0.00 3.96 4.65 5.03 4.93 4.01 4.93 5.36 7.05
NOPAT Less CapEx to Interest Expense
239.76 0.00 1.83 2.65 2.13 2.88 2.17 3.00 3.18 5.01
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 2.54% 3.40% 3.39% 3.12% 2.68%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 15.61% 3.40% 3.39% 3.12% 2.68%

Frequently Asked Questions About GE HealthCare Technologies' Financials

When does GE HealthCare Technologies's fiscal year end?

According to the most recent income statement we have on file, GE HealthCare Technologies' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has GE HealthCare Technologies' net income changed over the last 3 years?

GE HealthCare Technologies' net income appears to be on a downward trend, with a most recent value of $2.05 billion in 2024, falling from $2.29 billion in 2021. The previous period was $1.61 billion in 2023.

What is GE HealthCare Technologies's operating income?
GE HealthCare Technologies's total operating income in 2024 was $2.63 billion, based on the following breakdown:
  • Total Gross Profit: $8.21 billion
  • Total Operating Expenses: $5.58 billion
How has GE HealthCare Technologies revenue changed over the last 3 years?

Over the last 3 years, GE HealthCare Technologies' total revenue changed from $17.59 billion in 2021 to $19.67 billion in 2024, a change of 11.9%.

How much debt does GE HealthCare Technologies have?

GE HealthCare Technologies' total liabilities were at $24.44 billion at the end of 2024, a 2.8% decrease from 2023, and a 36.2% increase since 2022.

How much cash does GE HealthCare Technologies have?

In the past 2 years, GE HealthCare Technologies' cash and equivalents has ranged from $1.45 billion in 2022 to $2.89 billion in 2024, and is currently $2.89 billion as of their latest financial filing in 2024.

How has GE HealthCare Technologies' book value per share changed over the last 3 years?

Over the last 3 years, GE HealthCare Technologies' book value per share changed from 0.00 in 2021 to 18.49 in 2024, a change of 1,848.7%.

Remove Ads


This page (NASDAQ:GEHC) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners